aromasin
pfizer pfe pharmaceuticals israel ltd - exemestane - coated tablets - exemestane 25 mg - exemestane - exemestane - aromasin is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. aromasin is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.
aromasin 25 mg coated tablets
pco manufacturing ltd. - exemestane - coated tablet - 25 milligram(s) - aromatase inhibitors; exemestane
aromasin 25 mg coated tablets
imbat limited - exemestane - coated tablet - 25 milligram(s) - aromatase inhibitors; exemestane
aromasin 25 mg coated tablets
imed healthcare ltd. - exemestane - coated tablet - 25 milligram(s) - aromatase inhibitors; exemestane
estamane exemestane 25mg tablet blister pack
juno pharmaceuticals pty ltd - exemestane -
aromastan f.c. tablet 25mg
teva pharmaceutical investments singapore pte. ltd. - exemestane - tablet, film coated - exemestane 25 mg
exaccord 25 film coated tablet 25 mg
accord healthcare private limited - exemestane - tablet, film coated - exemestane 25 mg
exedral 25 film-coated tablet 25mg
goldplus universal pte ltd - exemestane - tablet, film coated - exemestane 25.0mg
exemestane 25mg film-coated tablets
accord healthcare limited - exemestane - film-coated tablet - exemestane 25 mg - endocrine therapy
exemestane 25mg film-coated tablets
central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - exemestane - film-coated tablet - exemestane 25 mg - endocrine therapy